arrow
M

Markus Wallwiener

University of Kiel
H指数:51
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial

Alpelisib和Fulvestrant在德国PRAEGNANT试验中纳入的PIK3CA突变的激素受体阳性HER2阴性晚期乳腺癌

2026-04-020
OAAI
Digital maternity care in Germany: a cross-sectional web-based survey on midwives' perceptions

德国数字产科护理:一项关于助产士感知的横断面网络调查

2026-01-200
OA
Preferred working time models and equal opportunities in gynecology and obstetrics: a sub-analysis of the trinational FARBEN survey focusing on German participants from Western and Eastern federal states

偏好工作时间模型与妇产科学中的平等机会:一项基于三国FARBEN调查的子分析,重点关注来自德国西部和东部联邦州的参与者

2025-12-010
PRE
Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis

早期乳腺癌男性患者辅助内分泌治疗应用的影响:来自一项德国大型真实世界理赔数据分析的结果

2025-10-010
OAAI
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer

原发转移性疾病与复发HER2-negative、激素受体阳性晚期乳腺癌患者的特征及预后比较

BREAST
IF7.9
2025-04-010
OAAI
The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer

IGF2BP1癌基因是卵巢癌中YAP1-driven基因表达的可m6A-dependent增强子

2025-02-240
OAAI
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
2024-10-162
OAAI
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
2024-07-130
OAAI
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept
2023-12-131
PRE